Symposia 4 - Quest for Perfection: Updating 'The Bethesda System for Reporting Thyroid Cytopathology' (TBSRTC)
Tracking # 20-1038352
$99999.00
There are no ratings for this course
Learn moreCourse overview
The editors (as moderators) and several key lead chapter authors will present the updates and proposed changes to the 3rd (2023) edition of the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). The pivotal role of FNA in the management of patients with thyroid nodules will be highlighted. The symposium will elaborate on diagnostic issues of practical importance. Clinical implications of the various cytopathologic interpretations and TBSRTC categories will be discussed as well as the management guidelines for each diagnostic category in light of the most recent ATA guidelines. The crucial role of a multidisciplinary approach will be emphasized throughout the presentation and there will be a separate discussion on integrating thyroid imaging findings with the FNA diagnoses. The symposium will also include updates on the use of new molecular markers employed to enhance the pre-operative diagnostic accuracy of thyroid FNA as well as used for prognostics and therapeutics (for personalized treatment). The session is being co-sponsored by the ASC and European Federation of Cytology Societies (EFCS).
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Clinical Laboratory Personnel
Clinical Laboratory Director
Clinical Laboratory Supervisor
Clinical Laboratory Technician
Clinical Laboratory Technologist
Public Health Director
Public Health Supervisor
Public Health Technologist
Disclosure statements
The faculty, committee members, Executive Board and staff who are in position to control the content of this activity are required to disclose to the ASC and to learners any financial relationships that have occurred within the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ASC has reviewed the disclosures and mitigated all relevant financial relationships.
The following individuals have reported financial relationships:
Michael Berry, SCT(ASCP)MBCM: Stockholder-Hologic
Jeffrey Krane, MD, PhD: Consultant - Hamamatsu Photonics
Oscar Lin, MD, PhD: Consultant – Hologic and Jansen
Liron Pantanowitz, MD: Consultant – Hamamatsu, Advisory Board for Ibex
Martha B. Pitman, MD, FIAC: Consultant – Adenocyte, LLC
Donna K. Russell, MEd, CT(ASCP), HT(ASCP): Advisory Board – Hologic Scientific
Christopher J. VandenBussche, MD, PhD: Ad hoc advisory board panel and Consultant – Roche
Paul VanderLaan, MD, PhD: Consultant – Gala Therapeutics